Phase 3 N=20 Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction
Hypertrichosis
Primary: Change in Hair Growth — 57.6; 52.1; 39.3; 29.9 % hair reduction — p=0.2879
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=751 A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C at Week 54 — -0.30; -0.48 A1C (%)
Phase 3 N=193 Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
Epilepsy With Simple or Complex Partial Onset Seizures
Primary: Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method — 0.444; 0.287 proportion of participants
Phase 3 N=136 Smoking Termination Enhancement Project (STEP)
Smoking
Primary: Percentage of Participants Who Abstained From Smoking at 10 and 30 Weeks Post Quit Day — 5; 9; 4; 9 number of participants
Phase 3 N=350 DHA Supplementation and Pregnancy Outcome
Pregnancy
Primary: Percentage of Total Fatty Acids by Weight — 4.7; 7.3; 4.8; 7.8 percentage of fatty acid
Phase 3 N=606 Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
Psoriatic Arthritis
Primary: Percent of Patients Achieving ACR20 Response Criteria on Secukinumab 75 or 150 mg vs. Placebo — 50.5; 50.0; 17.3 % participant — p=<0.0001
Phase 3 N=86 NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Swanson, Kotin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)-Combined Scores-Average of All Post-Dose Time-Points — 19.1; 12.1 units on a scale — p=<0.001
Phase 3 N=1,390 Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)
Infertility
Primary: Percentage of Participants With ≥1 Vital Pregnancy (Cumulative Vital Pregnancy Rate) — 31.1; 33.0 Percentage of Participants
Phase 3 N=287 Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.
Influenza
Primary: Number of Naive Subjects 6 to < 36 Months Old Reporting Solicited Local and Systemic Adverse Events (AEs) From Day 1 to Day 7 Following Each Vaccination. — 35; 20; 21…
Phase 3 N=439 Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone
Opioid-Induced Bowel Dysfunction
Primary: Mean Weekly Spontaneous Bowel Movements at Week 8 — 2.4; 3.2 SBMs/Week
Phase 3 N=815 Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects
Low Back Pain
Primary: Change From Baseline to Week 12 in Average Daily Pain Intensity Scores — 0.88; 1.92 units on a scale — p=<.00001
Phase 3 N=296 Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
Bipolar Depression
Primary: Change From Baseline (Visit 2) to End of Study (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -15.27; -18.48; 28.8; 28.5 Scores on a…
Phase 3 N=504 Safety and Efficacy of Oral Febuxostat in Subjects With Gout
Gout
Primary: Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL) — 22.5; 33.5; 17.0 percentage of participants
Phase 3 N=752 Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects
Low Back Pain
Primary: Change From Baseline to Week 12 in Average Daily Pain Intensity Scores — 0.94; 1.59 units on a scale — p=0.0012
Phase 3 N=1,382 DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
Post Menopausal Osteoporosis
Primary: Relative Percent Change From Baseline in Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4) at 12 Months — 3.8199; 5.0872; 4.8188 Percent Change — p=<0.001